Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endotheliam growth factor receptors

The demonstration that angiogenesis is required for the growth of solid tumors has fueled an intense interest in the development of new therapeutic strategies that target the tumor vasculature. Here we report the development of an immune-based antiangiogenic strategy that is based on the generation...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 99; no. 10; p. 7009
Main Authors Niederman, Thomas M J, Ghogawala, Zoher, Carter, Bob S, Tompkins, Hillary S
Format Journal Article
LanguageEnglish
Published Washington National Academy of Sciences 14.05.2002
Subjects
Cells
Genes
Immunology
Studies
Tumors
Online AccessGet full text

Cover

More Information
Summary:The demonstration that angiogenesis is required for the growth of solid tumors has fueled an intense interest in the development of new therapeutic strategies that target the tumor vasculature. Here we report the development of an immune-based antiangiogenic strategy that is based on the generation of T lymphocytes that possess a killing specificity for cells expressing vascular endothelial growth factor receptors (VEGFRs).
ISSN:0027-8424
1091-6490